Cargando…

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs

BACKGROUND: Long-term monotherapy with nucleos(t)ide analogs (NAs) represents the treatment option for the majority of patients with chronic hepatitis B (CHB), an aging population with a greater likelihood of comorbidities. We assessed the prevalence of concurrent non-hepatic diseases and the safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siakavellas, Spyros, Goulis, John, Manolakopoulos, Spilios, Triantos, Christos, Gatselis, Nikolaos, Tsentemidou, Eva, Kranidioti, Hariklia, Ζisimopoulos, Κonstantinos, Τsoulas, Christos, Dalekos, George, Papatheodoridis, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774663/ https://www.ncbi.nlm.nih.gov/pubmed/33414625 http://dx.doi.org/10.20524/aog.2020.0525

Ejemplares similares

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice
por: Papatheodoridi, Μargarita, et al.
Publicado: (2017)

Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
por: Kranidioti, Hariklia, et al.
Publicado: (2015)

The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C
por: Savvoula, Savvidou, et al.
Publicado: (2012)

Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis
por: Kranidioti, Hariklia, et al.
Publicado: (2018)

Aiming towards hepatitis C virus elimination in Greece
por: Papatheodoridis, George V., et al.
Publicado: (2019)

Elastography for Hepatic Fibrosis Severity in Chronic Hepatitis B or C
por: Papageorgiou, Maria-Vasiliki, et al.
Publicado: (2011)

The role of vitamin D receptor polymorphisms in the course of chronic hepatitis C infection
por: Tsounis, Efthymios P., et al.
Publicado: (2022)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues
por: Papadopoulos, Nikolaos, et al.
Publicado: (2018)

Role of band ligation for secondary prophylaxis of variceal bleeding
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2018)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
por: Papatheodoridi, Margarita, et al.
Publicado: (2020)

Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience
por: Manolakopoulos, Spilios, et al.
Publicado: (2015)

Bacterial infections in patients with liver cirrhosis: clinical characteristics and the role of C-reactive protein
por: Deutsch, Melanie, et al.
Publicado: (2018)

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

Epidemiology of hepatitis C in Greece
por: Triantos, Christos, et al.
Publicado: (2016)

Non-alcoholic fatty liver disease may develop in individuals with normal body mass index
por: Margariti, Ekaterini, et al.
Publicado: (2012)

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
por: Koustenis, Kanellos Rafail, et al.
Publicado: (2020)

Endotoxin Translocation and Gut Barrier Dysfunction Are Related to Variceal Bleeding in Patients With Liver Cirrhosis
por: Triantos, Christos, et al.
Publicado: (2022)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)

Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels
por: Sinakos, Emmanouil, et al.
Publicado: (2016)

Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts?
por: Kalafateli, Maria, et al.
Publicado: (2016)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Serum zonulin levels in patients with liver cirrhosis: Prognostic implications
por: Voulgaris, Theodoros A, et al.
Publicado: (2021)

Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
por: Peng, Jie, et al.
Publicado: (2015)

High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Lin, Ching-Chung, et al.
Publicado: (2019)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
por: Liu, Li
Publicado: (2020)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
por: Pastuch-Gawołek, Gabriela, et al.
Publicado: (2019)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy
por: Osiowy, Carla, et al.
Publicado: (2016)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
por: Li, Tao, et al.
Publicado: (2018)

Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss
por: Xue, Yan, et al.
Publicado: (2021)

The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients
por: Xu, Wen-Xiong, et al.
Publicado: (2021)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9hdi35256u7es1nlolbtr7dpko